Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 24;11:3704. doi: 10.1038/s41467-020-17525-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a ELISA measurement of FGF-2 levels in E0771-vector (n = 3) and E0771-FGF-2 tumor tissues (n = 4). P = 0.0032. b Tumor growth of E0771-vector and E0771-FGF-2 (n = 5, 6). c Tumor growth of vehicle- and anti-VEGF-treated E0771-vector (n = 5,6; P = 0.0002). Tumor growth rates of vehicle- and anti-VEGF-treated E0771-FGF-2 (n = 6). d Tumor growth of vehicle- and imatinib-treated E0771-vector (n = 5). Tumor growth rates of vehicle- and imatinib-treated E0771-FGF-2 (n = 6). e Tumor growth of vehicle- and anti-VEGF plus imatinib-treated E0771-vector (n = 5, 6; P = 0.0001). Tumor growth rates of vehicle- and anti-VEGF plus imatinib-treated E0771-FGF-2 (n = 6, 8; P = 0.0010). f CD31⁺ microvessels (red) and NG2⁺ pericytes (blue) in various drug-treated E0771-vector and E0771-FGF-2 cancers. Bar = 50 μm. g Quantification of microvessels (n = 10 each; P(Vehicle-treated-vector vs anti-VEGF-treated-vector) = 0.0009), pericyte coverage (n = 9/9/11/12; P(Vehicle-treated-vector vs anti-VEGF-treated-vector) = 0.0374) and pericyte area (n = 9/9/10/12) of vehicle- and anti-VEGF-treated E0771 vector and E0771-FGF-2. h Quantification of microvessels (n = 10/11/10/10; P(Vehicle-treated-vector vs imatinib-treated-vector) = 0.0009; P(Vehicle-treated-FGF-2 vs anti-VEGF-treated-FGF-2) = 0.0453), pericyte coverage (n = 9/9/11/11; P(Vehicle-treated-vector vs imatinib-treated-vector) = 0.0120; P(Vehicle-treated-FGF-2 vs imatinib-treated-FGF-2) = 0.0103) and pericyte area (n = 9/11/10/11; P(Vehicle-treated-vector vs imatinib-treated-vector) = 0.0038) of vehicle- and imatinib-treated E0771-vector and E0771-FGF-2. i Quantification of microvessels (n = 10/9/10/10; P(Vehicle-treated-vector vs combination-treated-vector) = 0.0006; P(Vehicle-treated-FGF-2 vs combination therapy-treated-FGF-2) = 0.0009), pericyte coverage (n = 9/9/11/9; P(Vehicle-treated-vector vs combination-treated-vector) = 0.0004) and pericyte area (n = 9/9/10/9; P(Vehicle-treated-FGF-2 vs combination-treated-FGF-2) = 0.0117) of vehicle- and anti-VEGF plus imatinib-treated E0771-vector and E0771-FGF-2 cancers. FGF-2^- = vector cancers; FGF-2⁺ = FGF-2 cancers; n.s. Not significant; *P < 0.05; **P < 0.01; ***P < 0.001; two-tailed Student t-test. The exact P-values indicate in panels. a–e; n indicates individual mice. Data presented as mean ± s.e.m. g–i; Data presented as mean from random images of 4 animals/group ± s.e.m. Experiments were repeated twice. Source data are provided as a Source Data file.